Share this article
Share this article
ORLANDO, Fla., March 1, 2021 /PRNewswire/ AllianceRx Walgreens Prime recently announced results from research analyzing data of females with multiple sclerosis (MS) who became pregnant, and the impact of adherence to their disease-modifying therapies (DMTs) on hospital utilization and cost. Researchers wanted to understand how non-adherence to their DMTs would impact healthcare cost and utilization over a two-year period. The findings suggest for those women continuing their therapy throughout pregnancy, hospitalization costs and use were lower, compared to those who discontinued their therapy. The retrospective study was conducted by Walgreens, in collaboration with AllianceRx Walgreens Prime, a leading specialty and home delivery pharmacy.
Global Opioid Use Disorder Market 25
DBMR has added a new report titled Global Opioid Use Disorder Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. In this credible report, a study about market overview is performed by considering market drivers, market restraints, opportunities and challenges. Moreover, this report contains significant data, current market trends, market environment, technological innovation, upcoming technologies and the technical progress in the allied industry. This is the most relatable, exclusive, and commendable market research report formulated by focusing on definite business needs. The competitive analysis conducted in this report covers strategic profiling of key market players, their core competencies, and competitive landscape. To gain meaningful market insights and thrive in this competitive market place, this
DBMR has added a new report titled
Global Opioid Use Disorder Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This
Global Opioid Use Disorder Market report underlines the specific study of the industry which explains what the market definition, classifications, applications, engagements, and global industry trends are. The market data analysed and evaluated in this report makes you achieve the business goals and objectives in preset time frame. It highlights a wide-ranging evaluation of the market’s growth prospects and restrictions. This report is very useful to all sizes of business which makes it simpler to take informed decisions regarding different facets of industry. This report truly acts as a backbone to the business.
By AllianceRx Walgreens Prime
A patient s medical history includes years of data reflecting their medical conditions, co-morbidities, medications, laboratory results and additional information related to their health and well-being. While this data can be valuable in helping doctors, pharmacists and other clinicians optimize patient care, the challenge often comes down to how it is accessed, stored and shared.
Health data can be housed within numerous silos, including data stores, electronic health records and health information exchanges, making it difficult for members of a patient s care team to share information and harness its collective insights. Despite comprehensive health data being critical for improving outcomes and providing timely and cost-effective care, it s not always readily available. This often requires patients to provide their information through a manual process, which presents more opportunities for human error.
Kesimpta Available Through AllianceRx for US Patients With Relapsing MS 4.2 (15)
Kesimpta (ofatumumab), the first self-administered B-cell therapy to treat relapsing forms of multiple sclerosis (MS), is now available via AllianceRx Walgreens Prime, one of the largest specialty and home delivery pharmacies operating in the U.S., to patients living in the country.
The specialty pharmacy which focuses on serving patients with rare, chronic, and complex conditions expressed its satisfaction when hearing that Novartis, the company that holds Kesimpta’s commercial rights, had selected it to distribute the medication.
“AllianceRx Walgreens Prime’s number one priority is helping patients achieve the best possible results when managing their chronic or rare disease,” Tracey James, senior vice president of pharmacy services at AllianceRx, said in a press release.